Spero Therapeutics, Inc. (SPRO)
- Previous Close
1.4350 - Open
1.4200 - Bid 1.3600 x 100
- Ask 1.4300 x 500
- Day's Range
1.4100 - 1.4500 - 52 Week Range
0.9900 - 1.9950 - Volume
110,038 - Avg. Volume
323,408 - Market Cap (intraday)
76.528M - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
3.30 - EPS (TTM)
0.4300 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.50
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
sperotherapeutics.comRecent News: SPRO
Performance Overview: SPRO
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SPRO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SPRO
Valuation Measures
Market Cap
77.07M
Enterprise Value
6.28M
Trailing P/E
3.33
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.78
Price/Book (mrq)
0.72
Enterprise Value/Revenue
0.06
Enterprise Value/EBITDA
0.24
Financial Highlights
Profitability and Income Statement
Profit Margin
21.98%
Return on Assets (ttm)
10.90%
Return on Equity (ttm)
24.95%
Revenue (ttm)
103.78M
Net Income Avi to Common (ttm)
22.81M
Diluted EPS (ttm)
0.4300
Balance Sheet and Cash Flow
Total Cash (mrq)
76.33M
Total Debt/Equity (mrq)
5.19%
Levered Free Cash Flow (ttm)
-9.9M